Search

Your search keyword '"HIV Envelope Protein gp120 metabolism"' showing total 2 results
Start Over Descriptor "HIV Envelope Protein gp120 metabolism" Region united states
2 results on '"HIV Envelope Protein gp120 metabolism"'

1. T-1249 development suspended.

Author

Huff B

Subjects
Drug Approval, Drug Industry, HIV Envelope Protein gp120 metabolism, HIV Envelope Protein gp41 administration & dosage, HIV Envelope Protein gp41 metabolism, HIV Fusion Inhibitors administration & dosage, HIV Fusion Inhibitors metabolism, HIV Infections drug therapy, Humans, Peptide Fragments administration & dosage, Peptide Fragments metabolism, Protein Binding, United States, HIV Envelope Protein gp41 therapeutic use, HIV Fusion Inhibitors therapeutic use, Peptide Fragments therapeutic use
Published
2003

2. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand.

Author

Berman PW, Huang W, Riddle L, Gray AM, Wrin T, Vennari J, Johnson A, Klaussen M, Prashad H, Köhne C, deWit C, and Gregory TJ

Subjects
Animals, Gene Products, env immunology, HIV Antibodies biosynthesis, HIV Antigens immunology, HIV Envelope Protein gp120 metabolism, HIV Infections prevention & control, HIV Infections virology, Humans, In Vitro Techniques, Macrophages virology, Neutralization Tests, Phenotype, Rabbits, Receptors, CXCR4 metabolism, Recombinant Proteins immunology, Thailand, United States, AIDS Vaccines, HIV-1 classification, HIV-1 immunology, Receptors, CCR5
Abstract

Recombinant envelope glycoproteins prepared from a subtype B (MN) strain and a subtype E (CM244) strain of HIV-1 were combined to create a bivalent vaccine (B/E) effective against viruses circulating in the United States and Asia. Combining the two antigens resulted in formulations that increased the breadth and potency of the inter-subtype neutralizing response. Antibodies to the bivalent vaccine formulation neutralized viruses possessing diverse phenotypes, including syncytia-inducing and non-syncytia-inducing primary isolates, viruses using either the CCR5 or the CXCR4 chemokine receptors, and viruses differing in their sensitivity to soluble CD4. These studies demonstrate for the first time that the magnitude and quality of the immune response to HIV-1 can be improved by combining recombinant envelope glycoproteins from different genetic subtypes., (Copyright 1999 Academic Press.)

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results